Reply to ‘Not credible: a subversion of science by the pharmaceutical industry. Commentary on A global comparison regarding patient access to cancer drugs (Annals of Oncology 2007, vol 18, Suppl 3, pp1-75)’ by Michel P Coleman
作者： B. Jönsson , F. Lichtenberg , N. Wilking
关键词: Cancer drugs 、 Oncology 、 Pharmaceutical industry 、 Medicine 、 Letter to the editor 、 Alternative medicine 、 Subversion 、 Internal medicine 、 Annals
摘要: Letter to the editor in response to: Not credible: A subversion of science by pharmaceutical industry. Commentary on global comparison regarding patient access cancer drugs / Michel P Coleman, Annals Oncology, vol 18, Suppl 3, pp. 1-75, 2007.
oup.com
oxfordjournals.org
core.ac.uk
vu.edu.au
paperity.org参考文章(6)
Robert H. Topel, Kevin M. Murphy, Measuring the Gains from Medical Research: An Economic Approach ,(2003)
B. Jönsson, N. Wilking, A global comparison regarding patient access to cancer drugs. Annals of Oncology. ,vol. 18, ,(2007) , 10.1093/ANNONC/MDM095
Robert H. Topel, Kevin M. Murphy, Measuring the Gains from Medical Research Research Papers in Economics. ,(2010)
Frank R. Lichtenberg, The Impact of New Drug Launches on Longevity: Evidence from Longitudinal, Disease-Level Data from 52 Countries, 1982?2001 International Journal of Health Care Finance and Economics. ,vol. 5, pp. 47- 73 ,(2005) , 10.1007/S10754-005-6601-7
Bryan R. Luce, Josephine Mauskopf, Frank A. Sloan, Jan Ostermann, L. Clark Paramore, The Return on Investment in Health Care: From 1980 to 2000 Value in Health. ,vol. 9, pp. 146- 156 ,(2006) , 10.1111/J.1524-4733.2006.00095.X
Martin J. Buxton, Substantial Returns to Health-Care Spending: But Do We Spend Too Little or Too Much? Value in Health. ,vol. 9, pp. 144- 145 ,(2006) , 10.1111/J.1524-4733.2006.00094.X